Ren Xiu Bao
Ren Xiu Bao — Chief Physician — Department of Biotherapy — Tianjin Medical University Cancer Hospital
Specialties
He has made outstanding achievements in the clinical and basic research of tumor immunotherapy, especially in organically combining conventional chemotherapy with modern biological therapy techniques (such as tumor vaccine therapy, CIK cell therapy, molecular targeted drug therapy, allogeneic hematopoietic stem cell transplantation immunotherapy, etc.), gradually forming a new model of individualized tumor biological therapy of 'chemotherapy-eliminate pathogens, immunity-strengthen the body.' He actively explores and promotes the development and application of new immunotherapy technologies and projects, and has carried out extensive clinical research in the treatment of solid tumors such as lung cancer, kidney cancer, malignant melanoma, and ovarian cancer, accumulating rich clinical experience.
Education
Graduated from Tianjin Second Medical College in 1989, obtained a master's degree in internal medicine from Bethune Medical University in 1996, and received a doctorate in oncology from Tianjin Medical University in 2006.
Professional Experience
Director of the Department of Biological Therapy for Tumors Professor Doctoral Supervisor Chief Physician Doctor of Medicine Director of the Biotechnology Research Laboratory, Tianjin Institute of Cancer Prevention and Treatment Engaged in tumor biological therapy and internal medicine treatment for 13 years, achieving remarkable accomplishments in both clinical treatment and basic research. Particularly, on the basis of conventional chemotherapy, integrating cell immunotherapy, allogeneic hematopoietic stem cell transplantation immunotherapy, tumor vaccine therapy, and other modern biological treatment techniques with molecular targeted drug therapy in an organic manner. Using this as a breakthrough, led the department to gradually form a personalized internal medicine treatment model for tumors. In clinical work, as the leader in biological therapy science, kept pace with world-leading fields, conducting extensive clinical research on the treatment of solid tumors such as lung cancer, kidney cancer, malignant melanoma, ovarian cancer, gastrointestinal tumors, and breast cancer, accumulating rich clinical experience and developing a distinctive comprehensive biological immunotherapy strategy. This treatment can improve patients' quality of life, extend survival, enhance chemotherapy efficacy, and reduce chemotherapy side effects. It has brought the biological therapy technology of Tianjin Cancer Hospital to a national leading level, achieving multiple important research results and outstanding clinical achievements. On average, more than 1,000 cases of various solid tumors and difficult cases are diagnosed and treated annually. As a key member of the task force, was the first in China to complete the largest clinical case study of “autologous peripheral blood hematopoietic stem cell transplantation combined with high-dose chemotherapy for solid tumors,” which nearly reduced the 3-year recurrence rate of high-risk breast cancer by 30%, earning the First Prize of the Chinese Medical Science and Technology Award (third author). In the field of allogeneic haploidentical hematopoietic stem cell immunotherapy for advanced malignant solid tumors, received funding from the 15th Guiding Project of the Ministry of Science and Technology. From 2006 to 2007, studied at Vanderbilt University in the United States, mainly focusing on the mechanism of tumor immune evasion. Fully utilized advanced technologies learned abroad, combined with the realities of domestic medical and scientific research work, actively conducting clinical and scientific research. By integrating advanced foreign tumor biological therapy technologies with existing domestic biological treatment methods, developed unique insights into the treatment of multiple solid tumors and achieved good therapeutic outcomes.
Professional Roles
Deputy Director and Secretary-General of the Clinical Application Professional Committee of the Chinese Society of Pharmaceutical Biotechnology Standing Committee Member of the Tumor Biotherapy Professional Committee of the Chinese Anti-Cancer Association Director of the Tianjin Anti-Cancer Association Member of the Sixth Council of the Chinese Society for Immunology Member of the Second Expert Group for Human Genetic Resources Management in China Standing Committee Member of the Lung Cancer Professional Committee of the Tianjin Anti-Cancer Association Standing Committee Member of the Cancer Rehabilitation and Palliative Care Professional Committee of the Tianjin Anti-Cancer Association Member of the Tissue Engineering Professional Committee of the Tianjin Society of Biomedical Engineering Deputy Director of the Tianjin Lung Cancer Diagnosis and Treatment Center Member of the Oncology Sub-Evaluation Committee of Tianjin Medical University